Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition

被引:87
作者
Kalvass, J. Cory
Pollack, Gary M.
机构
[1] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Chapel Hill, NC 27599 USA
关键词
absorption; blood-brain barrier; breast cancer resistance protein (BCRP); Caco-2; efflux inhibition; efflux ratio; efflux transporters; MDCK; multidrug resistance; P-glycoprotein; transcellular flux;
D O I
10.1007/s11095-006-9135-x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Unexpected and complex experimental observations related to efflux transport have been reported in the literature. This work was conducted to develop relationships for efflux activity (PSefflux) as a function of commonly studied kinetic parameters [permeability-surface area product (PS), efflux ratio (ER), degree of efflux inhibition (phi(i)), 50% inhibitory concentration (IC50), and Michaelis-Menten constant (K-m)]. Methods. A three-compartment model (apical, cellular, and basolateral) was used to derive flux equations relating the initial rate of flux and steady-state mass transfer in the presence or absence of active efflux. Various definitions of efflux ratio (ER) were examined in terms of permeability-surface area products. The efflux activity (PSefflux) was expressed in terms of ER and PS. The relationships between PSefflux and PS, ER, phi(i), IC50, and K-m were solved mathematically. Simulations and examples from the literature were used to illustrate the resulting mathematical relationships. Results. The relationships derived according to a three-compartment model differed fundamentally from commonly accepted approaches for determining PSefflux, phi(i), IC50 and K-m. Based on the model assumptions and mathematical derivations, currently used mathematical relationships erroneously imply that efflux activity is proportional to change in PS (i.e., flux or P-app) and thus underestimate PSefflux and phi(i,) and overestimate IC50 and K-m. Conclusions. An understanding of the relationship between efflux inhibition and kinetic parameters is critical for appropriate data interpretation, standardization in calculating and expressing the influence of efflux transport, and predicting the clinical significance of efflux inhibition.
引用
收藏
页码:265 / 276
页数:12
相关论文
共 31 条
[11]   Transporters and drug therapy: Implications for drug disposition and disease [J].
Ho, RH ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) :260-277
[12]   Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy [J].
Hulgan, T ;
Donahue, JP ;
Hawkins, C ;
Unutmaz, D ;
D'Aquila, RT ;
Raffanti, S ;
Nicotera, F ;
Rebeiro, P ;
Erdem, H ;
Rueff, M ;
Haas, DW .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (02) :119-126
[13]   Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice [J].
Kalvass, JC ;
Graff, CL ;
Pollack, GM .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1867-1870
[14]   The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice [J].
Kemper, EM ;
Cleypool, C ;
Boogerd, W ;
Beijnen, JH ;
van Tellingen, O .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :173-178
[15]   Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 [J].
Kruijtzer, CMF ;
Beijnen, JH ;
Rosing, H ;
Huinink, WWT ;
Schot, M ;
Jewell, RC ;
Paul, EM ;
Schellens, JHM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :2943-2950
[16]   Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2) [J].
Kusuhara, H ;
Sugiyama, Y .
DRUG DISCOVERY TODAY, 2001, 6 (04) :206-212
[17]   Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral Bioavailability of P-glycoprotein substrates [J].
Kwon, Hyojong ;
Lionberger, Robert A. ;
Yu, Lawrence X. .
MOLECULAR PHARMACEUTICS, 2004, 1 (06) :455-465
[18]   Drug-drug interaction mediated by inhibition and induction of P-glycoprotein [J].
Lin, JH .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) :53-81
[19]   Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation [J].
Matheny, CJ ;
Lamb, MW ;
Brouwer, KLR ;
Pollack, GM .
PHARMACOTHERAPY, 2001, 21 (07) :778-796
[20]   Tariquidar (TAR, XR-9576) selectively inhibits P-glycoprotein (P-GP) in T-lymphocytes compared to that in the blood-brain barrier (BBB). [J].
Muszkat, M ;
Kurnik, D ;
Sofowora, GG ;
Donahue, JP ;
Wilkinson, GR ;
Wood, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) :P39-P39